Concepedia

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy

Noah Rodriguez, J. Alejandro Rauh‐Hain, Melina Shoni, Ross S. Berkowitz, Michael G. Muto, Colleen M. Feltmate, John O. Schorge, Marcela G. del Carmen, Ursula A. Matulonis, Neil S. Horowitz

Gynecologic Oncology · 2012 · 72 citations · 26 references

DOI

Concepts

References

26

Cancer Statistics, 2010

Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text

Surg Clin North Am.

Rg. Martin · Medical Entomology and Zoology · 1986 · 8.8K citations

,

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, Claes G. Tropé, Frédéric Amant et al. · New England Journal of Medicine · 2010 · 2.5K citations · Full text

A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer

Robert C. Bast, Thomas L. Klug, Elena St. John et al. · New England Journal of Medicine · 1983 · 2.2K citations